Evidence map›Paper›PMID 32429869›Full record

ArticleBMC cancer2020

Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients.

Paula Whitmire, Cassandra R Rickertsen, Andrea Hawkins-Daarud, Eduardo Carrasco, Julia Lorence, Gustavo De Leon, Lee Curtin, Spencer Bayless, Kamala Clark-Swanson, Noah C Peeri and 16 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Multimodal Explainable Artificial Intelligence for Prognostic Stratification of Patients With Glioblastoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Sex-Specific Differences in Patients withAJNR. American journal of neuroradiology · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. PotentFrontiers in oncology · 2023
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 2 countries.

Paula WhitmirePrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA. paula.whitmire@gmail.com.
Cassandra R RickertsenPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Andrea Hawkins-DaarudPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Eduardo CarrascoPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Julia LorencePrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Gustavo De LeonPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Lee CurtinPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Spencer BaylessPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Kamala Clark-SwansonPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Noah C PeeriCancer Epidemiology Program, Moffitt Cancer Center, Tampa, FL, USA.
Christina CorpuzDepartment of Neurology, Columbia University Medical Center, New York, NY, USA.
Christine Paula Lewis-de Los AngelesNorthwestern University Interdepartmental Neuroscience Program, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Bernard R BendokPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Luis Gonzalez-CuyarDepartment of Pathology, Division of Neuropathology, University of Washington, Seattle, WA, USA.
Sujay VoraDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA.
Maciej M MrugalaDepartment of Neurology, Mayo Clinic, Phoenix, AZ, USA.
Leland S HuDepartment of Radiology, Mayo Clinic, Phoenix, AZ, USA.
Lei WangDepartment of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Alyx PorterDepartment of Neurology, Mayo Clinic, Phoenix, AZ, USA.
Priya KumthekarDepartment of Neurology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Sandra K JohnstonPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Kathleen M EganCancer Epidemiology Program, Moffitt Cancer Center, Tampa, FL, USA.
Robert GatenbyCancer Biology and Evolution Program, Moffitt Cancer Center, Tampa, FL, USA.
Peter CanollDivision of Neuropathology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.
Joshua B RubinDepartment of Pediatrics, Washington University School of Medicine, St Louis, MO, USA.
Kristin R SwansonPrecision Neurotherapeutics Innovation Program, Mayo Clinic, 5777 East Mayo Blvd , SSB 02-700, Phoenix, AZ, 85054, USA.
Mayo Clinic in Florida · USMayo Clinic Hospital · USMoffitt Cancer Center · USNorthwestern University · USColumbia University Irving Medical Center · USUniversity of Washington · USWashington University in St. Louis · US

Funding

James S. McDonnell Foundation 220020400
6 · The paper itself

Abstract

backgroundSex is recognized as a significant determinant of outcome among glioblastoma patients, but the relative prognostic importance of glioblastoma features has not been thoroughly explored for sex differences.

methodsCombining multi-modal MR images, biomathematical models, and patient clinical information, this investigation assesses which pretreatment variables have a sex-specific impact on the survival of glioblastoma patients (299 males and 195 females).

resultsAmong males, tumor (T1Gd) radius was a predictor of overall survival (HR = 1.027, p = 0.044). Among females, higher tumor cell net invasion rate was a significant detriment to overall survival (HR = 1.011, p < 0.001). Female extreme survivors had significantly smaller tumors (T1Gd) (p = 0.010 t-test), but tumor size was not correlated with female overall survival (p = 0.955 CPH). Both male and female extreme survivors had significantly lower tumor cell net proliferation rates than other patients (M p = 0.004, F p = 0.001, t-test).

conclusionDespite similar distributions of the MR imaging parameters between males and females, there was a sex-specific difference in how these parameters related to outcomes.

Indexed as

AdolescentAdultAgedAged, 80 and overBrain NeoplasmsChildFemaleFollow-Up StudiesGlioblastomaHumansImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedModels, TheoreticalPrognosisBiomathematical modelsGlioblastomaNeuroimagingSex differences

Identifiers

PMID32429869
PMCPMC7238585
OpenAlexW3028590342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.